Key Details
Price
$8.32Last Dividend
$0.10Annual ROE
17.30%Beta
1.01Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Oct 24, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Jan 05, 2022Next split:
N/ARecent split:
Jan 05, 2022Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Zynex Inc (NASDAQ:ZYXI) holds a competitive niche in the pain management market, benefiting from its focus on non-invasive, reimbursable solutions. While the company has successfully capitalized on the growing demand for non-opioid therapies, staying ahead will depend on its ability to innovate and adapt to a rapidly evolving medical device landscape.
Zynex Inc. (ZYXI) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.10 per share a year ago.
Zynex Inc (NASDAQ:ZYXI) announced its third-quarter 2024 financial and operational results highlighted by a 13% year-over-year increase in orders. The pain management device company reported net revenue of $50 million for the quarter ended September 30, 2024, up slightly from $49.9 million in the prior-year period.
ENGLEWOOD, Colo. , Oct. 24, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024.
ENGLEWOOD, Colo. , Oct. 16, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 24, 2024 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2024.
Analysts expect Zynex Inc (NASDAQ:ZYXI) to return to stronger growth in 2025, driven by product diversification, sales force expansion, and upcoming product launches. The company's strategic initiatives are seen as laying the groundwork for long-term success despite short-term hurdles.
Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard recently sat down with Proactive to discuss the medical device company's innovative solutions and impressive growth trajectory. Sandgaard highlighted how Zynex has expanded from a one-person operation 28 years ago to a company with 1,200 employees and revenues reaching $200 million.
ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.
ENGLEWOOD, Colo. , Sept. 4, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming HC Wainwright Global Investment Conference, which is being held September 9-11, 2024.
Zynex Inc (NASDAQ:ZYXI) announced that its portable pain management device TensWave has achieved Food and Drug Administration (FDA) clearance. The prescription-only TensWave device aims to provide pain relief through TENS (Transcutaneous Electrical Nerve Stimulation) therapy, which the company highlighted has been clinically proven to reduce chronic and acute pain without needing medication.
FAQ
- What is the primary business of Zynex?
- What is the ticker symbol for Zynex?
- Does Zynex pay dividends?
- What sector is Zynex in?
- What industry is Zynex in?
- What country is Zynex based in?
- When did Zynex go public?
- Is Zynex in the S&P 500?
- Is Zynex in the NASDAQ 100?
- Is Zynex in the Dow Jones?
- When was Zynex's last earnings report?
- When does Zynex report earnings?
- Should I buy Zynex stock now?